To include your compound in the COVID-19 Resource Center, submit it here.

Reata reports additional Phase II data for bardoxolone in Alport syndrome

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported additional data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE